12 recruiting, 11 not yet recruiting, 6 completed, 3 terminated. 19 Phase 2, 14 Phase 1, 5 Phase 3, 3 Not applicable, 1 Early Phase 1.
Follow Immune Thrombocytopenia (ITP): new trials by email Literature Review of Immune Thrombocytopenia (ITP) trials Research Report on Immune Thrombocytopenia (ITP)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias RXIM002 - Immune Thrombocytopenia (ITP) | Phase 1 | Not yet recruiting | RiboX Therapeutics Ltd. | 27 | 2027-02-01 | 2026-09-23 |
| A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA) | Phase 1 / Phase 2 | Not yet recruiting | Cullinan Therapeutics Inc. | 72 | 2026-12-01 | 2026-07-31 |
| Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases CHT105 - Immune Thrombocytopenia (ITP) | Not applicable | Not yet recruiting | Nanjing Miracle Biotechnology Co., Ltd. | 24 | 2026-09-01 | 2026-09-10 |
| Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions SKI-O-703 API in Capsules, SKI-O-703 Formulated Granules in Capsules - Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP) | Phase 1 | Active not recruiting | Oscotec Inc. | 48 | 2026-07-10 | 2026-09-01 |
| CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia Anti-CD20 monoclonal antibody and the BTK inhibitor - Anti-CD20 Monoclonal Antibody, BTK Inhibitors | Phase 1 | Not yet recruiting | Qi deng | 30 | 2026-06-01 | 2026-05-22 |
| A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia QT-019C - Immune Thrombocytopenia (ITP) | Early Phase 1 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 27 | 2026-02-20 | 2026-02-17 |
| A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) DZD8586 dose level 1, DZD8586 dose level 2, DZD8586 dose level 3 - Immune Thrombocytopenia (ITP) | Phase 2 | Recruiting | Dizal Pharmaceuticals | 60 | 2026-01-15 | 2026-01-22 |
| Fecal Microbiota Transplantation for Steroid-resistant or Relapsed Immune Thrombocytopenia Fecal microbiota transplantation - Immune Thrombocytopenia (ITP) | Phase 2 | Active not recruiting | Peking University People's Hospital | 42 | 2026-01-10 | 2026-07-29 |
| National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients Immune Thrombocytopenia (ITP) | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 500 | 2025-11-25 | 2025-12-08 | |
| A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia CM336 Injection - Autoimmune Cytopenia, Immune Thrombocytopenia (ITP) | Phase 1 / Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 158 | 2025-11-18 | 2025-12-17 |
| An Exploratory Study of Golidocitinib in Adult Patients With ITP Golidocitinib, Placebo - Immune Thrombocytopenia (ITP) | Phase 1 / Phase 2 | Not yet recruiting | Peking University People's Hospital | 138 | 2025-10-30 | 2025-09-29 |
| A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) Efgartigimod IV, Placebo IV - Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | argenx | 24 | 2025-10-20 | 2026-10-16 |
| Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia NVG-2089 - Immune Thrombocytopenia (ITP) | Phase 2 | Recruiting | Nuvig Therapeutics, Inc. | 30 | 2025-09-30 | 2026-09-14 |
| The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2) Teriflunomide, Dexamethasone - Immune Thrombocytopenia (ITP) | Phase 2 | Recruiting | Peking University People's Hospital | 132 | 2025-08-19 | 2025-09-08 |
| Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis. - Immune Thrombocytopenia (ITP) | Not applicable | Recruiting | Anhui Provincial Hospital | 18 | 2025-08-16 | 2025-08-08 |
| Level of Serum Lactate Dehydrogenase in Immune Thrombocytopenia Lactate dehydrogenase - Immune Thrombocytopenia (ITP) | Not yet recruiting | Sohag University | 40 | 2025-08-01 | 2025-07-01 | |
| A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia Pirtobrutinib, Placebo - Immune Thrombocytopenia (ITP) | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 68 | 2025-07-30 | 2026-10-09 |
| V-IMMUNE® for Immune Thrombocytopenia 5% (5g/100 ml) intravenous immunoglobin - Immune Thrombocytopenia (ITP) | Phase 3 | Recruiting | On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. | 31 | 2025-07-18 | 2026-01-20 |
| Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke Immune Thrombocytopenia (ITP), Acute Ischemic Stroke | Not yet recruiting | Peking University People's Hospital | 500 | 2025-07-10 | 2025-07-17 | |
| Longitudinal Observational Study on Immune Thrombocytopenia Immune Thrombocytopenia (ITP) | Not yet recruiting | Peking University People's Hospital | 2000 | 2025-07-10 | 2025-07-16 |
Showing 20 of 38. Sign in to see all of them.
Purpura, Thrombocytopenic, Idiopathic (38) · Anemia, Hemolytic, Autoimmune (3) · Antiphospholipid Syndrome (2) · Autoimmune Diseases (2) · Behcet Syndrome (2) · Blood Platelet Disorders (2) · Dermatomyositis (2) · Evans Syndrome (2) · Pemphigoid, Bullous (2) · Thrombocytopenia (2) · Anemia (1) · Anemia, Hemolytic (1) · Arthritis, Rheumatoid (1) · Connective Tissue Diseases (1) · Hematologic Diseases (1)
Blood Coagulation Disorders (38) · Cytopenia (38) · Hemic and Lymphatic Diseases (38) · Hemorrhage (38) · Hemorrhagic Disorders (38) · Immune System Diseases (38) · Pathologic Processes (38) · Pathological Conditions, Signs and Symptoms (38) · Purpura (38) · Purpura, Thrombocytopenic (38) · Signs and Symptoms (38) · Skin Manifestations (38) · Thrombotic Microangiopathies (38) · Hematologic Diseases (37) · Autoimmune Diseases (36)
Dexamethasone (3) · Rituximab (2) · Capsules (1) · Drugs, Investigational (1) · Fecal Microbiota Transplantation (1) · Immunoglobulins, Intravenous (1) · Octagam (1) · V-Set Domain-Containing T-Cell Activation Inhibitor 1 (1) · eltrombopag (1) · iguratimod (1) · iptacopan (1) · lusutrombopag (1) · pirtobrutinib (1) · romiplostim (1) · teriflunomide (1)
Peking University People's Hospital (6) · Institute of Hematology & Blood Diseases Hospital, China (3) · Assistance Publique - Hôpitaux de Paris (2) · Chugai Pharmaceutical (2) · Novartis Pharmaceuticals (2) · Anhui Provincial Hospital (1) · Bioverativ, a Sanofi company (1) · China Immunotech (Beijing) Biotechnology Co., Ltd. (1) · Climb Bio, Inc. (1) · Cullinan Therapeutics Inc. (1) · Dizal Pharmaceuticals (1) · Eli Lilly and Company (1) · Hutchison Medipharma Limited (1) · Keymed Biosciences Co.Ltd (1) · Kyowa Kirin China Pharmaceutical Co., Ltd. (1)
China (18) · Spain (7) · United States (7) · France (6) · Germany (6) · Italy (5) · Norway (4) · Poland (4) · United Kingdom (4) · Bulgaria (3) · Czechia (3) · Japan (3) · Netherlands (3) · Romania (3) · South Korea (3)
Xiao-Hui Zhang, MD (3) · Lei Zhang, MD (2) · Anders Waage, MD, PhD (1) · Heng Mei, Ph.D&M.D (1) · Hongyan Yin (1) · Israel Silva Maia, PhD (1) · Mahevas Matthieu (1) · Marc Michel, MD (1)
PMID 24517219, PMID 25662413, PMID 34921514, PMID 37028433, PMID 41366634, PMID 42114623
2019 (1), 2025 (1)